4 active shortage notices across 3 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Australia | critical | 1 | 5 Dec 2025 | 1 Sept 2026 | TGA |
| European Union | high | 1 | 17 Jan 2024 | — | EMA |
| United States | medium | 2 | 22 May 2024 | — | FDA MedWatch |
Yes. As of the latest regulator updates, Eptifibatide has 4 active shortage notices across 3 countries (Australia, European Union, United States). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Eptifibatide shortages to regulatory action, causes not stated by the regulator. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 1 Sept 2026 to 1 Sept 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Clopidogrel-Besilate · Dalteparin-Sodium · Rivaroxaban · Dipyridamole(25 Mg) · Acenocoumarol · Alteplase
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.